CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Béatrice Pignolet; Nicholas Schwab; Tilman Schneider-Hohendorf; Florence Bucciarelli; Damien Biotti; Delphine Averseng-Peaureaux; Olivier Outteryck; Jean Claude Ongagna; Jérôme De Sèze; Bruno Brochet; Jean Christophe Ouallet; Marc Debouverie; Sophie Pittion; Gilles Defer; Nathalie Derache; Patrick Hautecoeur; Ayman Tourbah; Pierre Labauge; Giovanni Castelnovo; Pierre Clavelou; Eric Berger; Jean Pelletier; Audrey Rico; Hélène Zéphir; David Laplaud; Sandrine Wiertlewski; William Camu; Eric Thouvenot; Olivier Casez; Thibault Moreau; Agnès Fromont; Sandra Vukusic; Caroline Papeix; Patrick Vermersch; Manuel Comabella; Christine Lebrun-Frenay; Heinz Wiendl; David Brassat

Article

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Neurology

DOI: 10.1212/WNL.0000000000003401

18Citations

36Readers

Get full text

Cite

CITATION STYLE

APA

Pignolet, B., Schwab, N., Schneider-Hohendorf, T., Bucciarelli, F., Biotti, D., Averseng-Peaureaux, D., … Brassat, D. (2016, December 6). CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology. Lippincott Williams and Wilkins. https://doi.org/10.1212/WNL.0000000000003401

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Cite

Register to see more suggestions